Literature DB >> 12218143

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses.

Steven C Fausch1, Diane M Da Silva, Michael P Rudolf, W Martin Kast.   

Abstract

High-risk human papillomaviruses are linked to several malignancies including cervical cancer. Because human papillomavirus-infected women do not always mount protective antiviral immunity, we explored the interaction of human papillomavirus with Langerhans cells, which would be the first APCs the virus comes into contact with during infection. We determined that dendritic cells, normally targeted by vaccination procedures and Langerhans cells, normally targeted by the natural virus equally internalize human papillomavirus virus-like particles. However, in contrast to dendritic cells, Langerhans cells are not activated by human papillomavirus virus-like particles, illustrated by the lack of: up-regulating activation markers, secreting IL-12, stimulating T cells in an MLR, inducing human papillomavirus-specific immunity, and migrating from epidermal tissue. Langerhans cells, like dendritic cells, can display all of these characteristics when stimulated by proinflammatory agents. These data may define an intriguing immune escape mechanism used by human papillomavirus and form the basis for designing optimal vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218143     DOI: 10.4049/jimmunol.169.6.3242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

Review 1.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

2.  Functional analysis of HPV-like particle-activated Langerhans cells in vitro.

Authors:  Lisa Yan; Andrew W Woodham; Diane M Da Silva; W Martin Kast
Journal:  Methods Mol Biol       Date:  2015

3.  Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro.

Authors:  Andrew W Woodham; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  Methods Mol Biol       Date:  2015

Review 4.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

5.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

Review 6.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

7.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

9.  Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.

Authors:  Rongcun Yang; Francisco Martinez Murillo; Hengmi Cui; Richard Blosser; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Therapeutic vaccines against human papillomavirus and cervical cancer.

Authors:  Angel Cid-Arregui
Journal:  Open Virol J       Date:  2009-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.